Cytochrome P-450 CYP2D6 Inhibitors
"Cytochrome P-450 CYP2D6 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2D6.
| Descriptor ID |
D065690
|
| MeSH Number(s) |
D27.505.389.500.368 D27.505.519.389.335.368
|
| Concept/Terms |
Cytochrome P-450 CYP2D6 Inhibitors- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P 450 CYP2D6 Inhibitors
- P450 CYP2D6 Inhibitors
- CYP2D6 Inhibitors, P450
- Inhibitors, P450 CYP2D6
- CYP2D6 Inhibitors
- Inhibitors, CYP2D6
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2D6 Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2D6 Inhibitors".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2D6 Inhibitors" by people in this website by year, and whether "Cytochrome P-450 CYP2D6 Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2D6 Inhibitors" by people in Profiles.
-
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry. 2019 12; 90(12):1317-1323.
-
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018 05; 103(5):770-777.
-
An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS. Biomed Chromatogr. 2016 Oct; 30(10):1556-72.
-
Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant? J Psychiatr Pract. 2011 Sep; 17(5):330-9.
-
Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. J Child Adolesc Psychopharmacol. 2011 Apr; 21(2):163-9.
-
Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen. J Clin Oncol. 2010 Oct 10; 28(29):e584-5; author reply e586.
-
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat. 2011 Jan; 125(1):279-87.
-
Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010 May; 38(5):871-8.